home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  October 01, 2016
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [4] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 660 active entries

LIONEX Diagnostics & Therapeutics GmbH

Salzdahlumer Str. 196
Braunschweig, 38126
Germany

Phone: 0049 531 260 12 66
Fax: 0049 531 260 11 59
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Description:

Lionex is a growing biotech company dedicated to modern biomedicine for human health. Lionex is developing protein-focused technologies to enable the accelerated identification, development and production of new and improved products (diagnostics, drugs and vaccines)  for combating major diseases, e.g. tuberculosis/HIV, heart diseases and cancer. Products: -Development of specific and rapid Tuberculosis diagnostic kits.
-Several serological kits (IgG,-A and -M) for Tuberculosis diagnosis have been developed showing high sensitivities and specifcities for pulmonary and extra-pulmonary TB. 

LIONEX  TB-ST+2, a second generation TB rapid tests for use with serum and blood has been launched. It provids results in 15 minutes and shows high specificity (99%) and high sensitivity (65%), specially in smear negative active TB.

-LIONEX continues to increase its panel of high quality mycobacterial antigens. The recombinant antigens are being used to develop test for sero-diagnosis of TB. Special attention is being given to cost-effective and rapid tests.

-In addition, based on proprietary methods rapid molecular tests have been developed for differentiating tuberculous bacteria from the nontuberculous ones.

-A rapid 3 hour test for differentiating M. tuberculosis from M. bovis has been developed.

Cancer: Lx-Bladder a cancer therapeutic is entering clincial trial inn humans.

Contract manufacturing: Large quantities of recombinant antigens, DNA, LAM



Selected Categories:
Product Company   Service Company
Biopharma
- Research
Diagnostics
- Immunoassay
- in vitro
- Medical
Pharmaceutical
- Research
Contract
- Production
- Research

Last update of this entry: June 15, 2016

Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.